Mezagitamab
TAK-079-3002
Phase 3 small_molecule active
Quick answer
Mezagitamab for Immune Thrombocytopenic Purpura (ITP) is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 2 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Immune Thrombocytopenic Purpura (ITP)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active